ASCO GU 2026 Highlights: Belzutifan + Lenvatinib and Pembrolizumab in RCC – IUCS

oncodaily - International Urology Cancer Summit shared a post on LinkedIn: “IUCS Journal Club – Highlights from ASCO GU 2026: Targeting HIF-2α in RCC. This Journal Club session reviews the data from […]

AI Summary: At ASCO GU, investigators showcased belzutifan‑based combinations for renal cell carcinoma, including belzutifan with lenvatinib and perioperative belzutifan plus pembrolizumab. Data presented indicate these HIF‑2α‑targeted regimens can extend disease‑free intervals in high‑risk clear‑cell RCC, prompting interest in integrating hypoxia‑axis inhibitors into multimodal kidney‑cancer care.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Rezatapopt shows proof-of-concept reactivating mutant p53 in patients / 2 months

Perioperative enfortumab vedotin plus pembrolizumab improves outcomes in MIBC / 3 months

TTLC 2026 highlights advanced NSCLC symposia and emerging data / 3 months

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival / 2 months

HORMAD1 emerges as a potential target in triple‑negative breast cancer / 2 months

Roche’s hoped‑for breast cancer pill fails crucial first‑line trial / 2 months

Romiplostim prevents chemo-induced platelet crashes in phase 3 trial / 2 months